These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24515308)

  • 1. Budget impact analysis of chronic kidney disease mass screening test in Japan.
    Kondo M; Yamagata K; Hoshi SL; Saito C; Asahi K; Moriyama T; Tsuruya K; Konta T; Fujimoto S; Narita I; Kimura K; Iseki K; Watanabe T
    Clin Exp Nephrol; 2014 Dec; 18(6):885-91. PubMed ID: 24515308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of chronic kidney disease mass screening test in Japan.
    Kondo M; Yamagata K; Hoshi SL; Saito C; Asahi K; Moriyama T; Tsuruya K; Yoshida H; Iseki K; Watanabe T
    Clin Exp Nephrol; 2012 Apr; 16(2):279-91. PubMed ID: 22167460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of mass screening for dipstick hematuria in Japan.
    Okubo R; Hoshi SL; Kimura T; Kondo M; Asahi K; Iseki C; Fujimoto S; Narita I; Nishiyama H; Yamagata K; Iseki K
    Clin Exp Nephrol; 2022 May; 26(5):398-412. PubMed ID: 35000032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behaviour modification intervention for patients with chronic kidney disease could provide a mid- to long-term reduction in public health care expenditure: budget impact analysis.
    Okubo R; Kondo M; Hoshi SL; Kai H; Saito C; Iseki K; Iseki C; Watanabe T; Narita I; Matsuo S; Makino H; Hishida A; Yamagata K
    Clin Exp Nephrol; 2022 Jun; 26(6):601-611. PubMed ID: 35084644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.
    Yarnoff BO; Hoerger TJ; Simpson SK; Leib A; Burrows NR; Shrestha SS; Pavkov ME;
    BMC Nephrol; 2017 Mar; 18(1):85. PubMed ID: 28288579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
    Arrospide A; Rue M; van Ravesteyn NT; Comas M; Soto-Gordoa M; Sarriugarte G; Mar J
    BMC Cancer; 2016 Jun; 16():344. PubMed ID: 27251556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea.
    Go DS; Kim SH; Park J; Ryu DR; Lee HJ; Jo MW
    Nephrology (Carlton); 2019 Jan; 24(1):56-64. PubMed ID: 29206319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of urine dipstick and albumin:creatinine ratio for chronic kidney disease screening: A population-based study.
    Park JI; Baek H; Kim BR; Jung HH
    PLoS One; 2017; 12(2):e0171106. PubMed ID: 28151999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies and cost-effectiveness evaluation of persistent albuminuria screening among high-risk population of chronic kidney disease.
    Wang H; Yang L; Wang F; Zhang L
    BMC Nephrol; 2017 Apr; 18(1):135. PubMed ID: 28420333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between urine albumin-to-creatinine ratio and urine protein dipstick testing for prevalence and ability to predict the risk for chronic kidney disease in the general population (Iwate-KENCO study): a prospective community-based cohort study.
    Koeda Y; Tanaka F; Segawa T; Ohta M; Ohsawa M; Tanno K; Makita S; Ishibashi Y; Itai K; Omama SI; Onoda T; Sakata K; Ogasawara K; Okayama A; Nakamura M
    BMC Nephrol; 2016 May; 17(1):46. PubMed ID: 27169575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective.
    Ferguson TW; Tangri N; Tan Z; James MT; Lavallee BDA; Chartrand CD; McLeod LL; Dart AB; Rigatto C; Komenda PVJ
    Kidney Int; 2017 Jul; 92(1):192-200. PubMed ID: 28433383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for chronic kidney disease of uncertain aetiology in Sri Lanka: usability of surrogate biomarkers over dipstick proteinuria.
    Ratnayake S; Badurdeen Z; Nanayakkara N; Abeysekara T; Ratnatunga N; Kumarasiri R
    BMC Nephrol; 2017 Jun; 18(1):199. PubMed ID: 28629425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of children with chronic kidney disease through school urinary screening using urinary protein/creatinine ratio measurement: an observational study.
    Kajiwara N; Hayashi K; Fujiwara M; Nakayama H; Ozaki Y
    Clin Exp Nephrol; 2020 May; 24(5):450-457. PubMed ID: 32006130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional variance in the use of urine dipstick test for outpatients in Japan.
    Nishi H; Yoshida Y; Inoue R; Takemura K; Nangaku M
    Nephrology (Carlton); 2020 Sep; 25(9):676-682. PubMed ID: 32243023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels.
    Yoshizawa T; Okada K; Furuichi S; Ishiguro T; Yoshizawa A; Akahoshi T; Gon Y; Akashiba T; Hosokawa Y; Hashimoto S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1283-9. PubMed ID: 26185434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for chronic kidney diseases among an adult population.
    Fatema K; Abedin Z; Mansur A; Rahman F; Khatun T; Sumi N; Kobura K; Akter S; Ali L
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):534-41. PubMed ID: 23640626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.